MD Anderson Ovarian SPORE publications – 2006
1.
Antoni MH, Lutgendorf SK, Cole SW, Dhabhar FS, Sephton SE, McDonald PG, Stefanek M, Sood AK.
The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev
Cancer 6(3):240-8, 2006. PMID: 16498446; PMCID: PMC3146042.
2.
Badr H, Basen-Engquist K, Carmack Taylor CL, de Moor C. Mood states associated with transitory
physical symptoms among breast and ovarian cancer survivors. J Behav Med 29(5):461-75, 2006.
PMID: 16705484.
3.
Barcenas CH, Hosain GM, Arun B, Zong J, Zhou X, Chen J, Cortada JM, Mills GB, Tomlinson GE,
Miller AR, Strong LC, Amos CI. Assessing BRCA carrier probabilities in extended families. J Clin
Oncol 24(3):354-60, 2006. PMID: 16421416.
4.
Bartholomeusz C, Itamochi H, Nitta M, Saya H, Ginsberg MH, Ueno NT. Antitumor effect of E1A in
ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15. Oncogene 25(1):79-90,
2006. PMID: 16170361.
5.
Brewer M, Kirkpatrick ND, Wharton JT, Wang J, Hatch K, Auersperg N, Utzinger U, Gershenson D,
Bast R, Zou C. 4-HPR modulates gene expression in ovarian cells. Int J Cancer 119(5):1005-13,
2006. PMID: 16570282.
6.
Broaddus RR, Lu KH. Women with HNPCC: a target population for the chemoprevention of
gynecologic cancers. Front Biosci 11:2077-80, 2006. PMID: 16720294.
7.
Bussey KJ, Chin K, Lababidi S, Reimers M, Reinhold WC, Kuo WL, Gwadry F, Ajay, Kouros-Mehr H,
Fridlyand J, Jain A, Collins C, Nishizuka S, Tonon G, Roschke A, Gehlhaus K, Kirsch I, Scudiero DA,
Gray JW, Weinstein JN. Integrating data on DNA copy number with gene expression levels and
drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther 5(4):853-67, 2006. PMID:
16648555; PMCID: PMC2733874.
8.
Canada AL, Parker PA, de Moor JS, Basen-Engquist K, Ramondetta LM, Cohen L. Active coping
mediates the association between religion/spirituality and quality of life in ovarian cancer.
Gynecol Oncol 101(1):102-7, 2006. PMID: 16256181.
9.
Chang KH, Albarracin C, Luthra R, Wang L, Zheng W, Malpica A, Deavers MT, Silva EG, Liu J.
Discordant genetic changes in ovarian and endometrial endometrioid carcinomas: a potential
pitfall in molecular diagnosis. Int J Gynecol Cancer 16(1):178-82, 2006. PMID: 16445630.
10.
Chatterjee M, Mohapatra S, Ionan A, Bawa G, Ali-Fehmi R, Wang X, Nowak J, Ye B, Nahhas FA, Lu K,
Witkin SS, Fishman D, Munkarah A, Morris R, Levin NK, Shirley NN, Tromp G, Abrams J, Draghici S,
Tainsky MA. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and
detection on arrays. Cancer Res 66(2):1181-90, 2006. PMID: 16424057; PMCID: PMC2546578.
11.
Coleman RL, Broaddus RR, Bodurka DC, Wolf JK, Burke TW, Kavanagh JJ, Levenback CF,
Gershenson DM. Phase II trial of imatinib mesylate in patients with recurrent platinum- and
taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol 101(1):126-31,
2006. PMID: 16271384.
12.
Coleman RL, Sood AK. Historical progress in the initial management of ovarian cancer:
intraperitoneal chemotherapy. Curr Oncol Rep 8(6):455-64, 2006. PMID: 17040624.
13.
Coleman RL. Intraperitoneal chemotherapy for frontline ovarian cancer therapy: vindicated or
vilified? Curr Oncol Rep 8(6):439-40, 2006. PMID: 17091543.
14.
Davidson B, Zhang Z, Kleinberg L, Li M, Florenes VA, Wang TL, Shih Ie M. Gene expression
signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal
mesothelioma. Clin Cancer Res 12(20 Pt 1):5944-50, 2006. PMID: 17062665.
15.
Davies M, Hennessy B, Mills GB. Point mutations of protein kinases and individualised cancer
therapy. Expert Opin Pharmacother 7(16):2243-61, 2006. PMID: 17059381.
16.
de Moor JS, de Moor CA, Basen-Engquist K, Kudelka A, Bevers MW, Cohen L. Optimism, distress,
health-related quality of life, and change in cancer antigen 125 among patients with ovarian
cancer undergoing chemotherapy. Psychosom Med 68(4):555-62, 2006. PMID: 16868264.
17.
Farley J, Bast RC Jr, Birrer MJ. Biomarkers and clinical trial design. Gynecol Oncol 103(2 Suppl
1):S3-5, 2006. PMID: 17027069.
18.
Fu S, Hu W, Kavanagh JJ, Bast RC Jr. Targeting Aurora kinases in ovarian cancer. Expert Opin
Ther Targets 10(1):77-85, 2006. PMID: 16441230.
19.
Fu S, Kavanagh JJ, Hu W, Bast RC Jr. Clinical application of oxaliplatin in epithelial ovarian
cancer. Int J Gynecol Cancer 16(5):1717-32, 2006. PMID: 17009963.
20.
Gallion H, Christopherson WA, Coleman RL, DeMars L, Herzog T, Hosford S, Schellhas H, Wells A,
Sevin BU. Progression-free interval in ovarian cancer and predictive value of an ex vivo
chemoresponse assay. Int J Gynecol Cancer 16(1):194-201, 2006. PMID: 16445633.
21.
Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, Deavers MT, Silva EG, Bodurka
DC. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol
108(2):361-8, 2006. PMID: 16880307.
22.
Gossner G, Coleman RL, Mutch DG, Horowitz NS, Rader JS, Gibb RK, Powell MA, Herzog TJ. CA-125
response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated
liposomal doxorubicin or topotecan. Gynecol Oncol 103(1):212-8, 2006. PMID: 16677696.
23.
Halder J, Kamat AA, Landen CN, Jr, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB,
Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK.
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral
liposomes for ovarian carcinoma therapy. Clin Cancer Res 12(16):4916-24, 2006. PMID: 16914580;
PMCID: PMC3144499.
24.
Han LY, Landen CN, Jr, Kamat AA, Lopez A, Bender DP, Mueller P, Schmandt R, Gershenson DM,
Sood AK. Preoperative serum tissue factor levels are an independent prognostic factor in
patients with ovarian carcinoma. J Clin Oncol 24(5):755-61, 2006. PMID: 16380413.
25.
Han LY, Landen CN, Trevino JG, Halder J, Lin YG, Kamat AA, Kim TJ, Merritt WM, Coleman RL,
Gershenson DM, Shakespeare WC, Wang Y, Sundaramoorth R, Metcalf CA, 3rd, Dalgarno DC,
Sawyer TK, Gallick GE, Sood AK. Antiangiogenic and antitumor effects of SRC inhibition in
ovarian carcinoma. Cancer Res 66(17):8633-9, 2006. PMID: 16951177; PMCID: PMC3202609.
26.
Hefler LA, Zeillinger R, Grimm C, Sood AK, Cheng WF, Gadducci A, Tempfer CB, Reinthaller A.
Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian
cancer. Gynecol Oncol 103(2):512-7, 2006. PMID: 16750560.
27.
Hennessy BT, Mills GB. Ovarian cancer: homeobox genes, autocrine/paracrine growth, and
kinase signaling. Int J Biochem Cell Biol 38(9):1450-6, 2006. PMID: 16682246.
28.
Hennessy BT, Nanjundan M, Cheng KW, Nolden L, Mills GB. Identification of remodeling and
spacing factor 1 (rsf-1, HBXAP) at chromosome 11q13 as a putative oncogene in ovarian cancer.
Eur J Hum Genet 14(4):381-3, 2006. PMID: 16418735.
29.
Herzog TJ, Coleman RL, Markman M, Cella D, Thigpen JT. The role of maintenance therapy and
novel taxanes in ovarian cancer. Gynecol Oncol 102(2):218-25, 2006. PMID: 16460787.
30.
Hu L, Ferrara N, Jaffe RB. Paracrine VEGF/VE-cadherin action on ovarian cancer permeability.
Exp Biol Med (Maywood) 231(10):1646-52, 2006. PMID: 17060686.
31.
Kamat AA, Bischoff FZ, Dang D, Baldwin MF, Han LY, Lin YG, Merritt WM, Landen CN, Jr, Lu C,
Gershenson DM, Simpson JL, Sood AK. Circulating cell-free DNA: a novel biomarker for response
to therapy in ovarian carcinoma. Cancer Biol Ther 5(10):1369-74, 2006. PMID: 16969071.
32.
Kamat AA, Fletcher M, Gruman LM, Mueller P, Lopez A, Landen CN, Jr, Han L, Gershenson DM, Sood
AK. The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin
Cancer Res 12(6):1707-14, 2006. PMID: 16551853; PMCID: PMC3202606.
33.
Kamat AA, Sood AK, Dang D, Gershenson DM, Simpson JL, Bischoff FZ. Quantification of total
plasma cell-free DNA in ovarian cancer using real-time PCR. Ann N Y Acad Sci 1075:230-4, 2006.
PMID: 17108216.
34.
Klostergaard J, Auzenne E, Ghosh S, Farquhar D, Rivera B, Price RE. Magnetic resonance imagingbased prospective detection of intraperitoneal human ovarian carcinoma xenografts treatment
response. Int J Gynecol Cancer 16 Suppl 1:111-7, 2006. PMID: 16515577.
35.
Kong F, Nicole White C, Xiao X, Feng Y, Xu C, He D, Zhang Z, Yu Y. Using proteomic approaches
to identify new biomarkers for detection and monitoring of ovarian cancer. Gynecol Oncol
100(2):247-53, 2006. PMID: 16229881.
36.
Kuo MT, Wei Y, Yang X, Tatebe S, Liu J, Troncoso P, Sahin A, Ro JY, Hamilton SR, Savaraj N.
Association of fragile site-associated (FSA) gene expression with epithelial differentiation and
tumor development. Biochem Biophys Res Commun 340(3):887-93, 2006. PMID: 16386706.
37.
Kwong J, Lee JY, Wong KK, Zhou X, Wong DT, Lo KW, Welch WR, Berkowitz RS, Mok SC. Candidate
tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and
histone hypoacetylation in human epithelial ovarian cancer. Neoplasia 8(4):268-78, 2006. PMID:
16756719; PMCID: PMC1600675.
38.
Landen CN, Jr, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG,
Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, Parikh NU, Gallick GE, Kinch MS,
Sood AK. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in
ovarian cancer. J Natl Cancer Inst 98(21):1558-70, 2006. PMID: 17077358.
39.
Landen CN, Merritt WM, Mangala LS, Sanguino AM, Bucana C, Lu C, Lin YG, Han LY, Kamat AA,
Schmandt R, Coleman RL, Gershenson DM, Lopez-Berestein G, Sood AK. Intraperitoneal delivery of
liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther 5(12):1708-13, 2006.
PMID: 17106249.
40.
Lee EJ, Deavers MT, Hughes JI, Lee JH, Kavanagh JJ. Metastasis to sigmoid colon mucosa and
submucosa from serous borderline ovarian tumor: response to hormone therapy. Int J Gynecol
Cancer 16 Suppl 1:295-9, 2006. PMID: 16515607.
41.
Lee Z, Swaby RF, Liang Y, Yu S, Liu S, Lu KH, Bast RC Jr, Mills GB, Fang X. Lysophosphatidic acid
is a major regulator of growth-regulated oncogene alpha in ovarian cancer. Cancer Res
66(5):2740-8, 2006. PMID: 16510595.
42.
Lorenzi PL, Reinhold WC, Rudelius M, Gunsior M, Shankavaram U, Bussey KJ, Scherf U, Eichler GS,
Martin SE, Chin K, Gray JW, Kohn EC, Horak ID, Von Hoff DD, Raffeld M, Goldsmith PK, Caplen NJ,
Weinstein JN. Asparagine synthetase as a causal, predictive biomarker for L-asparaginase
activity in ovarian cancer cells. Mol Cancer Ther 5(11):2613-23, 2006. PMID: 17088436.
43.
Lu Z, Luo RZ, Peng H, Rosen DG, Atkinson EN, Warneke C, Huang M, Nishmoto A, Liu J, Liao WS, Yu
Y, Bast RC Jr. Transcriptional and posttranscriptional down-regulation of the imprinted tumor
suppressor gene ARHI (DRAS3) in ovarian cancer. Clin Cancer Res 12(8):2404-13, 2006. PMID:
16638845.
44.
Mei FC, Young TW, Liu J, Cheng X. RAS-mediated epigenetic inactivation of OPCML in oncogenic
transformation of human ovarian surface epithelial cells. Faseb j 20(3):497-9, 2006. PMID:
16384911.
45.
Merritt WM, Thaker PH, Landen CN, Jr, Deavers MT, Fletcher MS, Lin YG, Han LY, Kamat AA,
Schmandt R, Gershenson DM, Kinch MS, Sood AK. Analysis of EphA2 expression and mutant p53
in ovarian carcinoma. Cancer Biol Ther 5(10):1357-60, 2006. PMID: 16969087.
46.
Morgan RJ, Jr, Alvarez RD, Armstrong DK, Chen LM, Copeland L, Fowler J, Gaffney DK, Gershenson
D, Greer BE, Johnston C, Lancaster JM, Lele S, Matulonis U, Ozols RF, Remmenga SW, Sabbatini P,
Soper J, Teng N. Ovarian cancer. Clinical practice guidelines in oncology. J Natl Compr Canc
Netw 4(9):912-39, 2006. PMID: 17020669.
47.
Nakayama K, Ueno NT. American Society of Clinical Oncology recommendations on fertility
preservation should be implemented regardless of disease status or previous treatments. J Clin
Oncol 24(33):5334-5; author reply 7-8, 2006. PMID: 17114671.
48.
O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL,
Baselga J, Rosen N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and
activates Akt. Cancer Res 66(3):1500-8, 2006. PMID: 16452206; PMCID: PMC3193604.
49.
Park JT, Li M, Nakayama K, Mao TL, Davidson B, Zhang Z, Kurman RJ, Eberhart CG, Shih Ie M, Wang
TL. Notch3 gene amplification in ovarian cancer. Cancer Res 66(12):6312-8, 2006. PMID:
16778208.
50.
Parker PA, Kudelka A, Basen-Engquist K, Kavanagh J, de Moor J, Cohen L. The associations
between knowledge, CA125 preoccupation, and distress in women with epithelial ovarian
cancer. Gynecol Oncol 100(3):495-500, 2006. PMID: 16242759.
51.
Prowse AH, Manek S, Varma R, Liu J, Godwin AK, Maher ER, Tomlinson IP, Kennedy SH. Molecular
genetic evidence that endometriosis is a precursor of ovarian cancer. Int J Cancer 119(3):556-62,
2006. PMID: 16506222.
52.
Rai R, Dai H, Multani AS, Li K, Chin K, Gray J, Lahad JP, Liang J, Mills GB, Meric-Bernstam F, Lin SY.
BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell
10(2):145-57, 2006. PMID: 16872911; PMCID: PMC1557410.
53.
Ramirez PT, Slomovitz BM, McQuinn L, Levenback C, Coleman RL. Role of appendectomy at the
time of primary surgery in patients with early-stage ovarian cancer. Gynecol Oncol 103(3):888-90,
2006. PMID: 16806436.
54.
Reed NS, Poole CJ, Coleman R, Parkin D, Graham JD, Kaye SB, Ostrowski J, Duncan I, Paul J, Hay
A. A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: a
study by the Scottish Gynaecological Cancer Trials Group (SGCTG). Eur J Cancer 42(2):179-85,
2006. PMID: 16337372.
55.
Rosen DG, Cai KQ, Luthra R, Liu J. Immunohistochemical staining of hMLH1 and hMSH2 reflects
microsatellite instability status in ovarian carcinoma. Mod Pathol 19(11):1414-20, 2006. PMID:
16941012.
56.
Rosen DG, Mercado-Uribe I, Yang G, Bast RC Jr, Amin HM, Lai R, Liu J. The role of constitutively
active signal transducer and activator of transcription 3 in ovarian tumorigenesis and
prognosis. Cancer 107(11):2730-40, 2006. PMID: 17063503.
57.
Rosen DG, Yang G, Bast RC Jr, Liu J. Use of Ras-transformed human ovarian surface epithelial
cells as a model for studying ovarian cancer. Methods Enzymol 407:660-76, 2006. PMID:
16757360.
58.
Rosen DG, Yang G, Deavers MT, Malpica A, Kavanagh JJ, Mills GB, Liu J. Cyclin E expression is
correlated with tumor progression and predicts a poor prognosis in patients with ovarian
carcinoma. Cancer 106(9):1925-32, 2006. PMID: 16568440.
59.
Schmandt RE, Bennett M, Clifford S, Thornton A, Jiang F, Broaddus RR, Sun CC, Lu KH, Sood AK,
Gershenson DM. The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the
ovary. Cancer Biol Ther 5(9):1136-41, 2006. PMID: 16855388.
60.
Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB, Daniels MS, White KG, BoydRogers SG, Conrad PG, Yang KY, Rubin MM, Sun CC, Slomovitz BM, Gershenson DM, Lu KH.
Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J
Med 354(3):261-9, 2006. PMID: 16421367.
61.
Schmeler KM, Sun CC, Bodurka DC, White KG, Soliman PT, Uyei AR, Erlichman JL, Arun BK, Daniels
MS, Rimes SA, Peterson SK, Slomovitz BM, Milam MR, Gershenson DM, Lu KH. Prophylactic
bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations.
Obstet Gynecol 108(3 Pt 1):515-20, 2006. PMID: 16946209.
62.
See HT, Thomas DA, Bueso-Ramos C, Kavanagh J. Secondary leukemia after treatment with
paclitaxel and carboplatin in a patient with recurrent ovarian cancer. Int J Gynecol Cancer 16
Suppl 1:236-40, 2006. PMID: 16515597.
63.
Silva EG, Gershenson DM, Malpica A, Deavers M. The recurrence and the overall survival rates of
ovarian serous borderline neoplasms with noninvasive implants is time dependent. Am J Surg
Pathol 30(11):1367-71, 2006. PMID: 17063075.
64.
Sood AK, Bhatty R, Kamat AA, Landen CN, Han L, Thaker PH, Li Y, Gershenson DM, Lutgendorf S,
Cole SW. Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res 12(2):36975, 2006. PMID: 16428474; PMCID: PMC3141061.
65.
Sood AK. Location matters. Gynecol Oncol 101(3):378-9, 2006. PMID: 16723288.
66.
Sood AK. Second look laparotomy for ovarian germ cell tumors: to do or not to do? J Postgrad
Med 52(4):246-7, 2006. PMID: 17191357.
67.
Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G,
Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix
E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf
SK, Cole SW, Sood AK. Chronic stress promotes tumor growth and angiogenesis in a mouse
model of ovarian carcinoma. Nat Med 12(8):939-44, 2006. PMID: 16862152.
68.
Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C,
Strong L, Arun B. Association between clinical characteristics and risk-reduction interventions in
women who underwent BRCA1 and BRCA2 testing: a single-institution study. Cancer
107(12):2745-51, 2006. PMID: 17109443.
69.
Vasey PA, Atkinson R, Osborne R, Parkin D, Symonds R, Paul J, Lewsley L, Coleman R, Reed NS,
Kaye S, Rustin GJ. SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as
first-line chemotherapy for ovarian cancer. Br J Cancer 94(1):62-8, 2006. PMID: 16404361; PMCID:
PMC2361073.
70.
Wang H, Rosen DG, Wang H, Fuller GN, Zhang W, Liu J. Insulin-like growth factor-binding protein
2 and 5 are differentially regulated in ovarian cancer of different histologic types. Mod Pathol
19(9):1149-56, 2006. PMID: 16729015.
71.
Wang X, Fu S, Freedman RS, Kavanagh JJ. Venous thromboembolism syndrome in gynecological
cancer. Int J Gynecol Cancer 16 Suppl 1:458-71, 2006. PMID: 16515646.
72.
Wang X, Fu S, Freedman RS, Liu J, Kavanagh JJ. Immunobiology of gestational trophoblastic
diseases. Int J Gynecol Cancer 16(4):1500-15, 2006. PMID: 16884358.
73.
Wen XF, Yang G, Mao W, Thornton A, Liu J, Bast RC Jr, Le XF. HER2 signaling modulates the
equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for
HER2-targeted antibody therapy. Oncogene 25(52):6986-96, 2006. PMID: 16715132.
74.
Wolf JK, Bodurka DC, Verschraegen C, Sun CC, Branham D, Jenkins AD, Atkinson N, Gershenson
DM. A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory
ovarian, fallopian tube, or peritoneal cancer. Gynecol Oncol 102(3):468-74, 2006. PMID: 16516276.
75.
Yang G, Rosen DG, Zhang Z, Bast RC Jr, Mills GB, Colacino JA, Mercado-Uribe I, Liu J. The
chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of
stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A 103(44):16472-7, 2006.
PMID: 17060621; PMCID: PMC1637606.
76.
Ye B, Skates S, Mok SC, Horick NK, Rosenberg HF, Vitonis A, Edwards D, Sluss P, Han WK,
Berkowitz RS, Cramer DW. Proteomic-based discovery and characterization of glycosylated
eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in
urine. Clin Cancer Res 12(2):432-41, 2006. PMID: 16428483.
77.
Yu W, Wu B, Liu J, Li X, Stone K, Williams KR, Zhao H. MALDI-MS data analysis for disease
biomarker discovery. Methods Mol Biol 328:199-216, 2006. PMID: 16785651.
78.
Yu Y, Luo R, Lu Z, Wei Feng W, Badgwell D, Issa JP, Rosen DG, Liu J, Bast RC Jr. Biochemistry and
biology of ARHI (DIRAS3), an imprinted tumor suppressor gene whose expression is lost in
ovarian and breast cancers. Methods Enzymol 407:455-68, 2006. PMID: 16757345.